 SAN DIEGO, March 10, 2021 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that will be presented as electronic posters during Week 1 of the American Association for Cancer Research AACR Annual Meeting 2021, taking place virtually from April 10-15, 2021. Details on the electronic posters and corresponding abstracts are shown below. 